RemSleep DeltaWave reclassified as implantable by FDA; must resubmit 510K after new testing

RemSleep Holdings Inc.

FDA reclassified DeltaWave as implantable device; company withdrawing current 510K application.
Additional testing required; RemSleep engaging consultants to satisfy new classification.
FDA confirmed all previously submitted test results will apply to the new 510K submission.
Company plans to submit next 510K for next-generation Nasal Pillows interface soon.
OTCQB application is in final stages of completion by securities attorney.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.